Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES ...
-- Phase 1/2 safety cohort enrollment complete: Eight (8) patients with invasive oral cavity cancer treated in the PRV211 safety cohort -- Primary safety endpoint met: Safety assessed by clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results